Synedica vs Alluvi vs VLS Retatrutide UK — Complete Brand Comparison 2025

Three retatrutide brands dominate the UK market — Synedica, Alluvi and VLS. All three are independently COA verified, but there are meaningful differences in dose options, pricing and reputation. Here’s our honest comparison based on buyer feedback and independent testing data.

At a Glance — Brand Comparison

Synedica Retatrutide — The UK Market Leader

Synedica is the UK’s most popular retatrutide brand — consistently our bestseller, with the strongest buyer reviews for product consistency and pen reliability. Synedica’s 40mg pen is the preferred choice for users who are established on their titration protocol (8mg+ weekly doses) and require the higher volume.

Buy: Synedica Retatrutide 40mg UK — £299 →

Pros: Market-leading reputation · Consistent COA scores · Reliable pen mechanism
Cons: 40mg only — no 20mg option for those preferring lower dose flexibility

Alluvi Retatrutide — Best for Flexible Titration

Alluvi’s key differentiator is the availability of both 20mg and 40mg pens. For users starting retatrutide for the first time or those who prefer titrating more slowly (staying at 2mg–6mg weekly doses for longer), the 20mg pen provides twice the number of doses per pen and allows finer control at lower dose levels.

Alluvi consistently scores well on independent COA testing and has strong buyer reviews, particularly among users who appreciate the lower dose flexibility.

Buy: Alluvi Retatrutide 40mg UK — £299 → · Alluvi Retatrutide 20mg UK — £249 →

Pros: 20mg option available · Good for slower titration · Strong COA scores
Cons: Slightly less name recognition than Synedica in the UK market

VLS Retatrutide — Best Value Brand

VLS offers the most competitive price in our retatrutide range at £265/month for the 40mg pen and £199/month for 20mg. VLS is a newer brand in the UK market but has established independent COA verification. For buyers who are price-sensitive or want to trial retatrutide before committing to higher-priced brands, VLS is a credible option.

Buy: VLS Retatrutide 40mg UK — £265 → · VLS Retatrutide 20mg UK — £199 →

Pros: Most competitive price · COA verified · 20mg option available
Cons: Less established UK buyer history than Synedica/Alluvi

Which Retatrutide Brand Should You Buy?

• First-time buyer: Alluvi 20mg (£249) — start slow, maximum flexibility
• Experienced buyer at 8mg+ weekly: Synedica 40mg (£299) — most trusted brand, maximum pen volume
• Price-conscious buyer: VLS 40mg (£265) — good value, COA verified
• Trying retatrutide for the first time on a budget: VLS 20mg (£199) — lowest entry cost

All three brands are independently COA verified at UK Peptides Store. Every order includes physician review, dosing protocol and 48hr UK delivery. Not sure? WhatsApp us for a personalised recommendation →

Compounded Semaglutide vs Ozempic® UK — Is the Active Molecule Really the Same?

The most common question UK buyers ask before purchasing compounded semaglutide: is it really the same drug as Ozempic®? The short answer is yes — the active pharmaceutical ingredient is identical. But understanding what’s different is just as important as knowing what’s the same.

What Is Semaglutide — The Active Molecule

Semaglutide is a GLP-1 receptor agonist — a synthetic peptide analogue of the natural hormone GLP-1 (glucagon-like peptide-1). It was developed by Novo Nordisk and approved by the FDA in 2017 (Ozempic®, NDA 209637) for type 2 diabetes and in 2021 (Wegovy®, NDA 215256) for chronic weight management.

The molecule itself is in the public domain in terms of its chemical structure — it is a 31-amino acid peptide with a specific fatty acid chain attachment. Licensed compounding pharmacies can legally synthesise this same molecule using pharmaceutical-grade API.

Compounded Semaglutide vs Ozempic® — Direct Comparison

The Critical Difference — MHRA Approval

Ozempic® is an MHRA-licensed medicine — it has undergone extensive clinical trials and regulatory review as a finished pharmaceutical product. Compounded semaglutide uses the identical active ingredient but is not an MHRA-licensed medicine. It is produced by licensed compounding pharmacies under specific regulatory frameworks that permit compounding of licensed drug ingredients.

This distinction matters for informed consent — but does not change the pharmacological action of the molecule. The GLP-1 receptor does not distinguish between Ozempic®’s semaglutide and compounded semaglutide at the molecular level.

Is Compounded Semaglutide Safe?

When produced by a PCAB-accredited compounding pharmacy and independently tested to ≥98% purity with COA verification, compounded semaglutide is produced to the same quality standards as other pharmaceutical-grade compounds. The FDA has published detailed guidance on compounded drug products that establishes the regulatory framework.

Safety risks with compounded semaglutide typically arise from:

• Underdosed or mislabelled products (unknown concentration)
• Products from non-accredited or unverified compounders
• Products without independent COA testing
• Use without physician oversight

None of these risks apply to verified, COA-tested compounded semaglutide from a licensed UK supplier with physician review — which is exactly what UK Peptides Store provides.

Why Is Compounded Semaglutide 80% Cheaper Than Ozempic®?

Ozempic® and Wegovy® prices are not set by production cost — they are set by Novo Nordisk’s pricing strategy, patent protection and the lack of direct competition. The actual cost of pharmaceutical-grade semaglutide API is a fraction of the brand-name retail price.

When patent protection expires and generic/biosimilar semaglutide enters the market, Ozempic® prices will fall dramatically — as has happened with every major pharmaceutical before it. Compounded semaglutide is simply accessing the same molecule at closer to its actual production cost.

Clinical Efficacy — Does Compounded Semaglutide Work as Well?

The clinical efficacy of a peptide is determined by the active molecule binding to the target receptor — not by the brand name on the pen. Compounded semaglutide at the same concentration and dose as Ozempic® will produce the same pharmacological effect in the body. The STEP 1 trial’s 14.9% weight loss result reflects the pharmacology of semaglutide — the molecule.

Buy Compounded Semaglutide UK

Buy compounded semaglutide UK from £199/month — physician-supervised, COA verified, ≥98% purity, 48hr UK delivery. Questions? WhatsApp our team →

Retatrutide vs Tirzepatide vs Mounjaro® — Full 2025 Comparison

With multiple powerful GLP-1 options available in the UK — retatrutide, tirzepatide, and brand-name Mounjaro® — choosing the right compound can be confusing. This guide provides a direct, evidence-based comparison to help you decide.

The Key Difference — Mechanism of Action

The addition of glucagon (GCG) receptor activation in retatrutide is the critical difference — it adds a third fat-burning mechanism that increases resting energy expenditure, a mechanism absent from tirzepatide and semaglutide.

Weight Loss Results — Head-to-Head Comparison

Sources: Retatrutide NEJM 2023 · Tirzepatide NEJM 2022 · Semaglutide NEJM 2021

Retatrutide vs Tirzepatide — The Practical Differences

Weight loss

Retatrutide produces meaningfully greater average weight loss (24.2% vs 22.5%). The difference becomes more pronounced at the high end — 83% of retatrutide patients lost ≥20% body weight vs 56% of tirzepatide patients. For someone weighing 100kg, this is the difference between losing ~22kg vs ~24kg on average — significant in absolute terms.

Side effects

Both have very similar GI side effect profiles. Retatrutide uniquely produces a modest heart rate increase (4–6 bpm average) due to glucagon receptor activation — this is absent with tirzepatide. For most healthy adults this is clinically insignificant, but relevant for those with cardiac concerns.

Evidence base

Tirzepatide has a larger evidence base — Phase 3 SURMOUNT trials enrolled thousands of participants across multiple years. Retatrutide’s Phase 2 data is compelling but Phase 3 results are still emerging. Tirzepatide is the more established compound with more long-term safety data.

Price in UK (2025)

• Compounded retatrutide 40mg: £299/month
• Compounded tirzepatide 20mg: from £199/month
• Mounjaro® brand (Rx): £1,050–£1,400/month

Retatrutide vs Mounjaro® — Are They the Same?

No — they are different molecules entirely. Mounjaro® contains tirzepatide (dual GLP-1/GIP agonist). Retatrutide is a triple GLP-1/GIP/GCG agonist. There is no brand-name retatrutide currently available — it has not yet received MHRA or FDA approval. Retatrutide is available in the UK only as a compounded research peptide.

Which Should You Choose?

Choose retatrutide if:

• You want maximum weight loss results
• You have tried semaglutide or tirzepatide with suboptimal results
• You are comfortable with the newer evidence base
• Budget is £299/month or above

Choose tirzepatide if:

• You want strong results with a better-established safety profile
• You prefer the dual agonist without glucagon effects
• Budget is tighter — effective from £199/month
• You have any cardiac history (avoid glucagon component)

Browse both: Synedica Retatrutide 40mg UK · Tirzepatide 20mg UK. Not sure which? WhatsApp our team →

Retatrutide Price UK 2025 — Full Cost Breakdown

Retatrutide price in the UK varies significantly between suppliers — from under £150 to over £600 per pen. This guide breaks down exactly what retatrutide costs in 2025, what drives price differences, what’s included at different price points, and why the cheapest option is almost always the most dangerous.

Retatrutide Price UK — Brand-by-Brand Comparison (2025)

Why Retatrutide Prices Vary So Much Online

A 40mg retatrutide pen can be found online for anywhere from £80 to £600. Here’s why:

Cheap retatrutide (under £200/40mg pen)

At these prices, something is missing. Retatrutide is an expensive molecule to synthesise correctly — the raw API alone costs significantly more than budget pricing suggests. Typical warning signs of cheap, potentially unsafe retatrutide:

• No Certificate of Analysis — or a COA from a non-independent lab
• Concentration unknown or underdosed (may be diluted)
• No physician review included
• Unknown or unverifiable compounding source
• Sourced from China without UK customs clearance

Premium retatrutide (£300–£450/40mg pen)

The realistic price range for pharmaceutical-grade retatrutide from a verifiable, COA-tested UK supplier. Includes independent lab verification, physician oversight and a proper dosing protocol.

Clinic pricing (£400–£800/month)

Private UK peptide clinics charge a significant premium for the consultation component — often £100–£200/month above the product cost. If you already have a physician, buying direct from a UK supplier like UK Peptides Store is significantly more cost-effective.

Annual Cost of Retatrutide UK — Budget Planning

• 1 month at £299 = £299
• 6 months at £299/month = £1,794
• 12 months at £299/month = £3,588
• Saving vs Mounjaro® brand (£1,050/month) over 12 months = £9,012

Why COA Verification Is Worth Paying For

Our retatrutide is verified by Janoshik Analytical — view Batch #81821 COA here. Independent third-party testing verifies:

• The compound is actually retatrutide (not a substitute)
• Purity is ≥98% (underdosed compounds are common in the market)
• No dangerous contaminants or residual solvents

Buy Retatrutide UK — Transparent Pricing

At UK Peptides Store, our retatrutide price includes everything: the pen, COA verification, physician review, personalised dosing protocol and 48hr discreet UK delivery — no hidden fees. View all retatrutide options →

Retatrutide Results UK — What to Expect Week by Week

What results should you realistically expect from retatrutide? This guide breaks down the clinical trial outcomes week by week, explains how individual results vary, and sets honest expectations for UK buyers starting a retatrutide protocol.

Retatrutide Phase 2 Results — The Clinical Evidence

The gold standard for retatrutide results comes from the Phase 2 trial published in the New England Journal of Medicine (2023), which followed 338 adults across four dose groups over 48 weeks:

For comparison: semaglutide 2.4mg (Wegovy®) produced 14.9% average weight loss in the STEP 1 trial. Tirzepatide 15mg (Mounjaro®) produced 22.5% in SURMOUNT-1.

Retatrutide Results Week by Week — Typical Timeline

Weeks 1–4 (2mg starting dose)

Most users notice subtle changes — slightly smaller appetite, meals feeling satisfying with less food. Don’t expect dramatic weight loss at the starting dose. This phase is about allowing your body to adapt. Average weight change: 0.5–1kg loss.

Weeks 5–8 (4mg dose)

Appetite suppression becomes clearer. Spontaneous reduction in calorie intake without intentional dieting. Average weight loss: 1–2kg over this period.

Weeks 9–12 (8mg dose)

This is typically where users notice the most significant change. Appetite is substantially reduced. Many report “food noise” diminishing — fewer intrusive thoughts about food. Average weight loss accelerates to 2–3kg per month at this stage.

Weeks 13–24 (12mg dose)

Peak weight loss phase for most users. Strong appetite suppression, increased energy expenditure from glucagon activation. Users who started at 100kg are typically at 80–85kg by week 24 on 12mg. Cumulative average: 15–22% body weight.

Week 24+ (Maintenance at 12–24mg)

Weight loss continues at a slower rate as the body approaches a new set point. Focus shifts to maintenance. At 24mg, the Phase 2 trial showed 24.2% average total weight loss at week 48.

Real Weight Loss Calculator — How Much Could You Lose?

Based on Phase 2 trial averages at the 12mg maintenance dose:

• Starting weight 80kg: Expected loss ~18kg → target weight ~62kg
• Starting weight 100kg: Expected loss ~23kg → target weight ~77kg
• Starting weight 120kg: Expected loss ~27kg → target weight ~93kg
• Starting weight 150kg: Expected loss ~34kg → target weight ~116kg

These are averages — individual results vary significantly based on diet, activity levels, metabolic health and protocol adherence.

What Affects Retatrutide Results?

• Diet: Retatrutide reduces appetite but doesn’t enforce food choices. Users who complement it with whole foods and reduced ultra-processed food see better results
• Activity: Even moderate exercise (walking 8,000+ steps/day) improves outcomes significantly
• Dose: Higher doses produce better results — but always titrate slowly to the lowest effective dose
• Adherence: Missing doses reduces effectiveness. Once-weekly injection on the same day produces the most consistent results
• Starting weight: Higher starting BMI tends to correlate with larger absolute weight loss in kg, though the percentage is similar

Beyond Weight Loss — Other Results to Expect

• Blood pressure reduction (average 8.5 mmHg systolic in the trial)
• Improved fasting glucose and insulin sensitivity
• Reduction in waist circumference (average 25.7cm at 24mg)
• Improved lipid profile (triglycerides, LDL reduction)
• Reduced liver fat (particularly relevant for NAFLD)
• Improved cardiovascular risk markers

Start Your Retatrutide Protocol

Buy Synedica Retatrutide 40mg UK or Alluvi Retatrutide 40mg UK from £299/month with physician-supervised protocol included. WhatsApp us for a personalised protocol based on your starting weight and goals.

Retatrutide Side Effects UK — What the Phase 2 Clinical Trial Data Shows

Understanding retatrutide side effects before you start is essential for safe and effective use. The good news: the side effect profile from Phase 2 trials is well-characterised, dose-dependent and largely manageable with proper titration. This guide covers every side effect reported in the NEJM Phase 2 trial, how common each is, and exactly what to do if you experience them.

The Most Common Retatrutide Side Effects (GI-Related)

Like all GLP-1 class peptides, the most common retatrutide side effects are gastrointestinal. They occur because GLP-1 receptors are present throughout the gut, and receptor activation slows gastric motility. The key facts:

• All GI side effects are dose-dependent — they increase with higher doses
• All GI side effects are typically transient — they reduce significantly after 4–6 weeks at a stable dose
• All GI side effects can be dramatically reduced with slow titration as per your physician protocol

Retatrutide Side Effects — Phase 2 Trial Frequency Data

Source: Jastreboff AM et al., NEJM 2023

How to Manage Retatrutide Nausea

Nausea is the most common retatrutide side effect and the most frequently cited reason for dose reduction or discontinuation in the trial. Here’s how to manage it effectively:

• Eat smaller meals: Retatrutide slows gastric emptying — large meals sit in the stomach longer and cause nausea. Eat 50–60% of your normal portion size
• Avoid high-fat, high-calorie meals on injection day and the day after — these are most likely to trigger nausea
• Time your injection: Many users find injecting at bedtime minimises nausea by sleeping through the peak effect period
• Stay hydrated: Dehydration worsens nausea — drink 2–3 litres of water daily
• Don’t lie down immediately after eating: Stay upright for at least 2 hours after meals
• Slow your titration: If nausea persists beyond week 3 at a new dose, do not escalate — wait until nausea resolves before increasing

Heart Rate Increase — The Glucagon Effect

Retatrutide’s glucagon (GCG) receptor activation produces a modest heart rate increase not typically seen with semaglutide or tirzepatide. In the Phase 2 trial, mean heart rate increased by approximately 4–6 beats per minute. This is generally well-tolerated in healthy adults but warrants monitoring in patients with pre-existing cardiovascular conditions.

If you notice palpitations or a significant heart rate increase at higher retatrutide doses, contact your physician. Do not increase your dose until this has been evaluated.

Retatrutide Side Effects vs Semaglutide and Tirzepatide

The GI side effect profiles are broadly similar across the GLP-1 class. Retatrutide’s unique addition is the modest heart rate increase from glucagon receptor activation.

Rare but Serious Side Effects — When to Seek Help

While uncommon, the following require immediate medical attention:

• Severe abdominal pain radiating to the back (may indicate pancreatitis — discontinue immediately)
• Significant palpitations or chest discomfort persisting beyond 24 hours
• Severe allergic reaction — rash, swelling, difficulty breathing (anaphylaxis — extremely rare)
• Severe, persistent vomiting preventing fluid intake (dehydration risk)
• Symptoms of gallbladder disease — GLP-1 class peptides increase gallstone risk with rapid weight loss

Retatrutide and Thyroid Risk — What You Need to Know

GLP-1 receptor agonists caused thyroid C-cell tumours in rodent studies. The clinical significance in humans is unknown. Retatrutide is contraindicated in individuals with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN 2). If you have any thyroid history, consult your physician before starting retatrutide.

Ready to Start Retatrutide Safely?

Buy Synedica Retatrutide 40mg UK or Alluvi Retatrutide 40mg UK from £299/month — every order includes a physician-reviewed titration protocol designed to minimise side effects. Have questions? WhatsApp our team →

Related: Retatrutide dosage guide · How retatrutide works · Retatrutide results

Retatrutide Dosage Guide UK 2025 — Complete Starting Dose & Titration Schedule

Getting your retatrutide dosage right is the single most important factor in achieving maximum results with minimal side effects. This guide covers everything you need to know: the correct starting dose, the weekly titration schedule from the Phase 2 clinical trial, how to calculate pen clicks for different doses, and how to adjust if you experience side effects.

Every order from UK Peptides Store includes a physician-reviewed dosing protocol personalised to your starting weight and goals. This guide provides the general framework — always follow your specific physician protocol.

Retatrutide Starting Dose — Why 2mg Matters

The Phase 2 trial published in the New England Journal of Medicine (2023) used a standardised titration protocol starting at 2mg once weekly. This low starting dose exists for a specific reason: it allows your GI system to adapt to GLP-1/GIP/GCG receptor activation before dose escalation.

Starting at 2mg rather than jumping to 4mg or 8mg dramatically reduces the incidence of nausea, vomiting and GI side effects. Many buyers who purchase retatrutide online and self-administer at higher starting doses experience significant side effects that could be entirely avoided with proper titration.

Standard Retatrutide Titration Schedule — Based on NEJM Phase 2 Trial

Important: The 24mg dose is a maximum, not a target. Many users achieve excellent results at 12mg and never need to escalate further. Always stay at the lowest dose that achieves your goals.

Retatrutide Pen Click Calculator

Retatrutide injection pens (Synedica, Alluvi) are pre-dosed. However, the number of clicks required depends on the pen you are using and its concentration. Your physician protocol will specify the exact number of clicks for each dose. As a general guide for a 40mg pen with standard dosing:

Note: Always confirm click dosing with your physician protocol. Pen click volume varies by brand and batch. Never guess — contact our support team if unsure.

When to Stay at a Dose — Don’t Rush Titration

The urge to escalate quickly is understandable — but patience with the titration schedule produces better long-term outcomes. Stay at a dose for the full 4 weeks even if you feel ready to increase earlier. Reasons to stay at your current dose longer:

• You are still experiencing nausea or vomiting at your current dose
• You are achieving good weight loss results and don’t need a higher dose
• You recently had a gastrointestinal illness or stress
• You skipped a dose and need to return to the previous dose level

What If I Miss a Retatrutide Dose?

• Within 5 days of missed dose: Take the missed dose as soon as you remember, then resume your regular weekly schedule
• More than 5 days late: Skip the missed dose entirely and resume your regular next injection day
• Never double dose: Do not take two doses to compensate for a missed one
• Extended gap (2+ weeks): Consider returning to the previous dose level and re-titrating up — discuss with your physician

Adjusting Retatrutide Dose for Side Effects

If you experience persistent nausea or vomiting (more than 3 days) after a dose increase, the correct approach is to return to your previous dose for an additional 4 weeks before attempting to increase again. Do not push through severe side effects — this is counterproductive and unnecessary.

How Long Does It Take for Retatrutide to Work at Each Dose?

• 2mg: Most users notice subtle appetite changes by week 2–3. Minimal weight loss at this dose.
• 4mg: Clearer appetite suppression. Weight loss of 0.5–1kg/month typical.
• 8mg: Significant appetite reduction. 1–2kg/month weight loss for most users.
• 12mg: Strong efficacy. 2–3kg/month typical. This is where most users see the most dramatic results.
• 24mg: Maximum efficacy. Phase 2 trial showed 24.2% total body weight loss over 48 weeks at this dose.

Where to Buy Retatrutide UK — Synedica & Alluvi Pens

UK Peptides Store stocks Synedica Retatrutide 40mg and Alluvi Retatrutide 40mg/20mg pens from £299/month. Every order includes your physician-reviewed dosing protocol and titration schedule. Dispatched from Manchester within 48 hours.

Read more: Retatrutide side effects guide · How retatrutide works · Retatrutide price UK

What Does Retatrutide Do? How the Triple Agonist Works

Retatrutide is a next-generation injectable peptide developed by Eli Lilly that simultaneously activates three separate metabolic receptors — GLP-1 (Glucagon-Like Peptide-1), GIP (Glucose-Dependent Insulinotropic Polypeptide) and GCG (Glucagon). This triple mechanism is what makes retatrutide the most potent weight loss compound in clinical development, producing up to 24.2% body weight reduction in Phase 2 trials — more than any GLP-1 drug ever tested.

But what exactly does retatrutide do inside the body? This guide breaks down the science, the clinical evidence and what to realistically expect.

The Triple Mechanism — What Retatrutide Actually Does

1. GLP-1 Receptor Activation (the Ozempic® effect)

Like semaglutide (Ozempic®) and tirzepatide (Mounjaro®), retatrutide activates GLP-1 receptors. This produces the well-documented effects that made Ozempic® famous:

• Suppresses appetite by signalling satiety to the brain’s hunger centres
• Slows gastric emptying — food sits in the stomach longer, extending feelings of fullness
• Stimulates glucose-dependent insulin secretion — lowers blood sugar without hypoglycaemia risk
• Reduces glucagon secretion — prevents the liver from releasing excess glucose

2. GIP Receptor Activation (the Mounjaro® extra effect)

Retatrutide also activates GIP receptors — the same dual mechanism that makes tirzepatide (Mounjaro®) stronger than semaglutide:

• Enhances GLP-1 effects by amplifying the appetite suppression signal
• Directly affects fat cells (adipocytes) — promotes fat oxidation and reduces fat storage
• Improves insulin sensitivity in peripheral tissues
• May reduce GLP-1 side effects by modulating the GI response

3. Glucagon (GCG) Receptor Activation (the retatrutide difference)

This is what sets retatrutide apart from every other GLP-1 drug. By also activating glucagon receptors, retatrutide does something no other approved or compounded weight loss compound does:

• Increases resting energy expenditure (REE) — your body burns more calories at rest
• Promotes direct fat oxidation — the liver is signalled to burn fat stores for fuel
• Accelerates metabolic rate — total daily energy expenditure is elevated
• Works synergistically with GIP to create a combined fat-burning effect that neither receptor produces alone

The glucagon component is why retatrutide produces meaningfully greater weight loss than tirzepatide despite both having GLP-1 and GIP activity — the addition of GCG agonism adds a third fat-burning pathway.

What Does Retatrutide Do for Weight Loss? — Clinical Trial Data

The Phase 2 clinical trial published in the New England Journal of Medicine (2023) enrolled 338 adults with obesity or overweight. At 48 weeks at the 24mg dose:

• Average weight loss: 24.2% of total body weight
• Participants losing ≥20%: 83%
• Participants losing ≥25%: 57%
• Waist circumference reduction: Average 25.7cm
• Systolic blood pressure reduction: Average 8.5 mmHg

For context — a person weighing 100kg could expect to lose approximately 24kg on retatrutide over 48 weeks. At lower maintenance doses (8mg and 12mg), average weight loss was 17.5% and 22.8% respectively.

How Retatrutide Compares to Other GLP-1 Peptides

What Does Retatrutide Do Beyond Weight Loss?

Weight loss is the headline — but retatrutide produces significant metabolic improvements across multiple biomarkers:

• Blood glucose: Substantial reductions in fasting glucose and HbA1c — relevant for pre-diabetic and T2D patients
• Blood pressure: Average systolic BP reduction of 8.5 mmHg at 24mg
• Triglycerides: Significant reductions in fasting triglycerides
• Liver fat: Retatrutide dramatically reduces hepatic fat content — potentially useful for NAFLD/MAFLD
• Cardiovascular risk markers: Improvements in multiple CVD risk factors consistent with other GLP-1 agents

What Does Retatrutide Feel Like? What to Expect Week by Week

Weeks 1–4 (2mg starting dose)

Most users report subtle appetite changes — meals feel satisfying with less food. Minimal side effects at this dose. Weight loss of 0.5–1kg in the first month is typical.

Weeks 5–12 (4mg–8mg)

Appetite suppression becomes more pronounced. Spontaneous calorie reduction of 30–50% is common without intentional dieting. Weight loss accelerates — typically 1–2kg per month at this stage.

Weeks 13–24 (12mg–24mg)

Maximum efficacy phase. Significant appetite suppression. Many users report thinking about food completely differently — reduced food noise, fewer cravings. Weight loss of 1.5–3kg per month at maintenance doses.

Is Retatrutide Available in the UK?

Retatrutide is not yet MHRA approved for clinical prescription — it is currently in Phase 3 trials. However, it is available in the UK as a compounded research peptide from licensed suppliers. At UK Peptides Store, we stock Synedica Retatrutide 40mg and Alluvi Retatrutide 40mg/20mg pens — independently COA verified, physician-supervised, from £299/month with 48hr UK delivery.

Ready to start? Read our complete retatrutide dosage guide or WhatsApp us for a free protocol recommendation.